NRx Current Deferred Revenue vs Net Tangible Assets Analysis

NRXPW Stock  USD 0.18  0.03  14.29%   
NRx Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating NRx Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NRx Pharmaceuticals is a good investment. Please check the relationship between NRx Pharmaceuticals Current Deferred Revenue and its Net Tangible Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NRx Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more information on how to buy NRx Stock please use our How to Invest in NRx Pharmaceuticals guide.

Current Deferred Revenue vs Net Tangible Assets

Current Deferred Revenue vs Net Tangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NRx Pharmaceuticals Current Deferred Revenue account and Net Tangible Assets. At this time, the significance of the direction appears to have totally related.
The correlation between NRx Pharmaceuticals' Current Deferred Revenue and Net Tangible Assets is 1.0. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of NRx Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of NRx Pharmaceuticals' Current Deferred Revenue and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of NRx Pharmaceuticals are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Current Deferred Revenue i.e., NRx Pharmaceuticals' Current Deferred Revenue and Net Tangible Assets go up and down completely randomly.

Correlation Coefficient

1.0
Relationship DirectionPositive 
Relationship StrengthVery Strong

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.
Most indicators from NRx Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NRx Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NRx Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more information on how to buy NRx Stock please use our How to Invest in NRx Pharmaceuticals guide.At this time, NRx Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 19.7 M in 2025, whereas Enterprise Value Over EBITDA is likely to drop (1.24) in 2025.
 2022 2023 2024 2025 (projected)
Total Operating Expenses44.4M27.6M31.7M32.9M
Cost Of Revenue4K5K4.5K4.3K

NRx Pharmaceuticals fundamental ratios Correlations

-0.59-0.840.980.00.85-0.91-0.440.97-0.67-0.440.9-0.470.97-0.47-0.82-0.85-0.480.97-0.740.230.51-0.710.74-0.520.51
-0.590.57-0.620.04-0.120.270.01-0.50.010.01-0.280.23-0.51-0.020.080.60.02-0.530.040.31-0.05-0.040.020.01-0.05
-0.840.57-0.92-0.05-0.650.720.31-0.80.390.31-0.830.55-0.80.330.541.00.35-0.790.44-0.27-0.250.47-0.460.32-0.25
0.98-0.62-0.920.020.81-0.88-0.420.95-0.59-0.420.91-0.520.95-0.45-0.75-0.93-0.460.95-0.660.230.44-0.650.67-0.450.44
0.00.04-0.050.020.19-0.05-0.820.240.34-0.820.27-0.70.23-0.5-0.16-0.05-0.790.230.210.01-0.29-0.320.290.29-0.29
0.85-0.12-0.650.810.19-0.92-0.680.91-0.72-0.680.95-0.580.91-0.72-0.98-0.65-0.720.9-0.860.370.51-0.940.97-0.530.51
-0.910.270.72-0.88-0.05-0.920.51-0.90.790.51-0.920.37-0.90.450.920.720.54-0.90.78-0.55-0.670.81-0.870.67-0.67
-0.440.010.31-0.42-0.82-0.680.51-0.650.141.0-0.680.84-0.650.840.670.321.0-0.640.38-0.1-0.140.74-0.760.09-0.14
0.97-0.5-0.80.950.240.91-0.9-0.65-0.59-0.650.95-0.651.0-0.64-0.88-0.82-0.691.0-0.720.210.44-0.810.84-0.450.44
-0.670.010.39-0.590.34-0.720.790.14-0.590.14-0.62-0.07-0.590.190.770.380.17-0.580.79-0.54-0.750.63-0.690.75-0.75
-0.440.010.31-0.42-0.82-0.680.511.0-0.650.14-0.680.84-0.650.840.670.321.0-0.640.38-0.1-0.140.74-0.760.09-0.14
0.9-0.28-0.830.910.270.95-0.92-0.680.95-0.62-0.68-0.680.94-0.67-0.89-0.83-0.720.94-0.730.40.46-0.840.87-0.470.46
-0.470.230.55-0.52-0.7-0.580.370.84-0.65-0.070.84-0.68-0.640.860.490.570.86-0.640.320.170.070.57-0.55-0.070.07
0.97-0.51-0.80.950.230.91-0.9-0.651.0-0.59-0.650.94-0.64-0.64-0.87-0.81-0.681.0-0.720.20.45-0.810.83-0.450.45
-0.47-0.020.33-0.45-0.5-0.720.450.84-0.640.190.84-0.670.86-0.640.70.350.86-0.630.640.19-0.160.75-0.760.14-0.16
-0.820.080.54-0.75-0.16-0.980.920.67-0.880.770.67-0.890.49-0.870.70.540.7-0.870.9-0.37-0.640.94-0.980.63-0.64
-0.850.61.0-0.93-0.05-0.650.720.32-0.820.380.32-0.830.57-0.810.350.540.36-0.810.46-0.23-0.260.47-0.470.32-0.26
-0.480.020.35-0.46-0.79-0.720.541.0-0.690.171.0-0.720.86-0.680.860.70.36-0.680.43-0.1-0.160.77-0.790.12-0.16
0.97-0.53-0.790.950.230.9-0.9-0.641.0-0.58-0.640.94-0.641.0-0.63-0.87-0.81-0.68-0.720.190.44-0.80.83-0.440.44
-0.740.040.44-0.660.21-0.860.780.38-0.720.790.38-0.730.32-0.720.640.90.460.43-0.72-0.16-0.660.79-0.840.66-0.66
0.230.31-0.270.230.010.37-0.55-0.10.21-0.54-0.10.40.170.20.19-0.37-0.23-0.10.19-0.160.43-0.330.36-0.440.43
0.51-0.05-0.250.44-0.290.51-0.67-0.140.44-0.75-0.140.460.070.45-0.16-0.64-0.26-0.160.44-0.660.43-0.380.53-0.81.0
-0.71-0.040.47-0.65-0.32-0.940.810.74-0.810.630.74-0.840.57-0.810.750.940.470.77-0.80.79-0.33-0.38-0.970.53-0.38
0.740.02-0.460.670.290.97-0.87-0.760.84-0.69-0.760.87-0.550.83-0.76-0.98-0.47-0.790.83-0.840.360.53-0.97-0.530.53
-0.520.010.32-0.450.29-0.530.670.09-0.450.750.09-0.47-0.07-0.450.140.630.320.12-0.440.66-0.44-0.80.53-0.53-0.8
0.51-0.05-0.250.44-0.290.51-0.67-0.140.44-0.75-0.140.460.070.45-0.16-0.64-0.26-0.160.44-0.660.431.0-0.380.53-0.8
Click cells to compare fundamentals

NRx Pharmaceuticals Account Relationship Matchups

NRx Pharmaceuticals fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets2.9M32.7M25.8M7.3M6.6M6.3M
Total Current Liabilities46.2M11.9M16.6M19.0M21.9M14.9M
Total Stockholder Equity(43.8M)20.8M7.4M(11.7M)(10.6M)(10.0M)
Net Debt(1.1M)(27.1M)(9.5M)4.6M4.1M4.3M
Retained Earnings(90.2M)(183.2M)(223.1M)(253.1M)(227.8M)(216.4M)
Accounts Payable3.2M3.7M2.1M4.6M5.3M5.6M
Cash1.9M27.6M20.1M4.6M5.3M8.6M
Non Current Assets Total11K15K21K431K387.9K368.5K
Non Currrent Assets Other11K15K21K431K495.7K520.4K
Cash And Short Term Investments1.9M27.6M20.1M4.6M5.3M8.6M
Common Stock Shares Outstanding34.3M46.9M65.8M7.6M8.7M8.3M
Liabilities And Stockholders Equity2.9M32.7M25.8M7.3M6.6M6.3M
Other Current Assets240K5.1M11.5M2.3M2.6M3.0M
Other Stockholder Equity46.4M204.0M230.3M241.3M277.5M291.4M
Total Liab46.7M11.9M18.4M19.0M21.9M15.7M
Total Current Assets2.9M32.7M25.8M6.9M7.9M10.8M
Common Stock43K59K67K84K75.6K71.8K
Short Long Term Debt Total797K518K10.5M9.2M10.5M11.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NRx Stock Analysis

When running NRx Pharmaceuticals' price analysis, check to measure NRx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRx Pharmaceuticals is operating at the current time. Most of NRx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRx Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.